Iain D. Milligan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Iain D. Milligan has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Aimee McGreal-Bellone
Department of Infectious Diseases, Beaumont Hospital , Dublin , Ireland
1 shared publication Alina Botgros
Directorate of Infection, Guy’s & St Thomas’ National Health Service Foundation Trust , London , UK
1 shared publicationAndrew J. Pollard
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom7National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom
1 shared publicationBenoit Callendret
Janssen, Pharmaceutical Companies of Johnson & Johnson, Leiden, the Netherlands
1 shared publication- Brendan O'KElly
Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland
1 shared publication Brian Angus
Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 7 December 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (1) , ofad612
A Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir
The optimum treatment for persistent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not known. Our case series, across 5 hospitals in 3 countries, describes 11 cases where persistent SARS-CoV-2 infection was successfully treated with prolonged courses (median, 10 days [range, 10–18 days]) of nirmatrelvir/ritonavir (Paxlovid). Most cases (9/11) had hematological malignancy and 10 (10/11) had received CD20-depleting therapy. The median duration of infection was 103 days (interquartile range, 85–138 days). The majority (10/11) were hospitalized, and 7 (7/11) had severe/critical disease. All survived and 9 of 11 demonstrated viral clearance, almost half (4/9) of whom received nirmatrelvir/ritonavir as monotherapy. This case series suggests that prolonged nirmatrelvir/ritonavir has a role in treating persistent infection.
- 7 December 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (1) , ofad612
Open AccessA Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir
The optimum treatment for persistent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not known. Our case series, across 5 hospitals in 3 countries, describes 11 cases where persistent SARS-CoV-2 infection was successfully treated with prolonged courses (median, 10 days [range, 10–18 days]) of nirmatrelvir/ritonavir (Paxlovid). Most cases (9/11) had hematological malignancy and 10 (10/11) had received CD20-depleting therapy. The median duration of infection was 103 days (interquartile range, 85–138 days). The majority (10/11) were hospitalized, and 7 (7/11) had severe/critical disease. All survived and 9 of 11 demonstrated viral clearance, almost half (4/9) of whom received nirmatrelvir/ritonavir as monotherapy. This case series suggests that prolonged nirmatrelvir/ritonavir has a role in treating persistent infection.
- Top Cited Papers
- 19 April 2016
- Published by American Medical Association (AMA) in JAMA
- Vol. 315 (15) , 1610-1623
Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines
Research from JAMA — Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines — A Randomized Clinical Trial
- 19 April 2016
- Published by American Medical Association (AMA) in JAMA
- Vol. 315 (15) , 1610-1623
Top Cited PapersSafety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines
Research from JAMA — Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines — A Randomized Clinical Trial